Erlanger Launches GI Trial To Increase Early Colon Cancer Detection
Monday, February 8, 2021
Erlanger Health System announces the beginning of a clinical trial looking at the use of artificial intelligence technology for improving polyp detection during colonoscopy with the ME-APDSTM device by Magentiq Eye LTD.
The trial utilizes artificial intelligence software during a routine screening colonoscopy to identify abnormalities called polyps in the lining of the colon. The researchers aim to increase polyp detection rates in patients with the AI acting as an extra set of eyes for the endoscopist.
The device’s software reads the video screen at the same time as the doctor performing the colonoscopy.
“With this system, we target to have more accurate colonoscopy tests and more polyps detected,” said Dr. Dror Zur, CEO of Magentiq Eye.
The AI software was taught how to detect abnormalities after being fed thousands of images showing these issues in various stages and forms.
“We think cancers that happen between colonoscopies are due to missed polyps hiding behind the folds or flat and difficult to find polyps,” said Dr. Arslan Kahloon, chief of gastroenterology at Erlanger Health System and principal physician for the Erlanger research team in this trial. “So if we can find these polyps with any kind of extra detection system then we can deal with them accordingly.”
There is no additional risk or cost to patients compared to regular colonoscopy with an increased amount of polyps removed.
The study is officially open and recruiting participants. For more information or to make an appointment visit, Erlanger.org or call 778-4830. The study is in collaboration with the University of Tennessee Medical School and CTN2 Clinical Trials of Tennessee.